Published 1 month ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases - iBio (AMEX:IBIO)

Summary by Ground News

iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets. $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration. Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration.

0 Articles

All

Left

Center

Right

Benzinga

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases - iBio (AMEX:IBIO)

– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8…

1 month ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.